Radiation, chemotherapy, and symptom management in cancer-related cognitive dysfunction

Current Pain and Headache Reports

Volumn 13, Issue 4, 2009, Pages 271-276

  Loiselle, Christopher ^a   Rockhill, Jason ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARMUSTINE; CISPLATIN; CYTARABINE; DEXAMETHASONE; DONEPEZIL; FLUOROURACIL; METHYLPHENIDATE; MODAFINIL; MORPHINE; NARCOTIC ANALGESIC AGENT; PETHIDINE;

BRAIN EDEMA; BRAIN METASTASIS; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COGNITIVE REHABILITATION; DELIRIUM; DEMENTIA; HUMAN; LYMPHOMA; MEMORY DISORDER; MOTOR COORDINATION; NEUROTOXICITY; NONHUMAN; PREVALENCE; PSYCHOMOTOR PERFORMANCE; RADIATION INJURY; RADIATION NECROSIS; REVIEW; SIDE EFFECT; VERBAL MEMORY;

ANTINEOPLASTIC AGENTS; COGNITION DISORDERS; DISEASE MANAGEMENT; HUMANS; NEOPLASMS; QUALITY OF LIFE; RADIATION INJURIES;

EID: 67651095607     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-009-0043-8     Document Type: Review

References (52)

1. President's Cancer Panel: Cancer Care Issues in the United States: Quality of Care, Quality of Life. Bethesda, MD: National Cancer Program, National Cancer Institute; 1999.
2. Merriam-Webster Online: Definition of cognitive. Available at http://www.merriam-webster.com/dictionary/cognitive. Accessed November 2008.
3. Nieder C, Leicht A, Motaref B, et al.: Late radiation toxicity after whole brain radiotherapy: The influence of antiepileptic drugs. Am J Clin Oncol 1999, 22: 573-579.
4. Wefel JS, Witgert ME, Meyers CA: Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychol Rev 2008, 18: 121-131.
5. Hermelink K, Untch M, Lux MP, et al.: Cognitive function during neoadjuvant chemotherapy for breast cancer: Results of a prospective, multicenter, longitudinal study. Cancer 2007, 109: 1905-1913.
6. Ahles TA, Saykin AJ, McDonald BC, et al.: Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 2008, 110: 143-152.
7. Schagen SB, Muller MJ, Boogerd W, et al.: Change in cognitive function after chemotherapy: A prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 2006, 98: 1742-1745.
8. Hurria A, Rosen C, Hudis C, et al.: Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: A pilot prospective longitudinal study. J Am Geriatr Soc 2006, 54: 925-931.
9. Hurricane Voices Breast Cancer Foundation: Cognitive changes related to cancer treatment. Available at http://www.hurricanevoices.org/downloads/ hv_cognitive_results.pdf. Accessed November 2008.
10. Meyers CA, Albitar M, Estey E: Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005, 104: 788-793.
11. Meyers CA, Byrne KS, Komaki R: Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer 1995, 12: 231-235.
12. Ahles TA, Saykin AJ, Furstenberg CT, et al.: Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002, 20: 485-493.
13. Tucha O, Smely C, Preier M, et al.: Cognitive deficits before treatment among patients with brain tumors. Neurosurgery 2000, 47: 324-333; discussion 333-334.
14. Laack NN, Brown PD, Ivnik RJ, et al.: Cognitive function after radiotherapy for supratentorial low-grade glioma: A North Central Cancer Treatment Group prospective study. Int J Radiat Oncol Biol Phys 2005, 63: 1175-1183.
15. Armstrong CL, Hunter JV, Ledakis GE, et al.: Late cognitive and radiographic changes related to radiotherapy: Initial prospective findings. Neurology 2002, 59: 40-48.
16. Torres IJ, Mundt AJ, Sweeney PJ, et al.: A longitudinal neuropsychological study of partial brain radiation in adults with brain tumors. Neurology 2003, 60: 1113-1118.
17. Archibald YM, Lunn D, Ruttan LA, et al.: Cognitive functioning in long-term survivors of high-grade glioma. J Neurosurg 1994, 80: 247-253.
18. Bosma I, Vos MJ, Heimans JJ, et al.: The course of neurocognitive functioning in high-grade glioma patients. Neuro Oncol 2007, 9: 53-62.
19. Taphoorn MJ, Klein M: Cognitive deficits in adult patients with brain tumours. Lancet Neurol 2004, 3: 159-168.
20. Oneschuk D, Bruera E: Palliative management of brain metastases. Support Care Cancer 1998, 6: 365-372.
21. DeAngelis LM, Delattre JY, Posner JB: Radiation-induced dementia in patients cured of brain metastases. Neurology 1989, 39: 789-796.
22. Aoyama H, Tago M, Kato N, et al.: Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 2007, 68: 1388-1395.
23. Kurita GP, Lundorff L, Pimenta CA, et al.: The cognitive effects of opioids in cancer: A systematic review. Support Care Cancer 2009; 17: 11-21.
24. Ersek M, Cherrier MM, Overman SS, et al.: The cognitive effects of opioids. Pain Manag Nurs 2004, 5: 75-93.
25. Bataller L, Dalmau JO: Paraneoplastic disorders of the central nervous system: Update on diagnostic criteria and treatment. Semin Neurol 2004, 24: 461-471.
26. Miller AH, Ancoli-Israel S, Bower JE, et al.: Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol 2008, 26: 971-982.
27. Dantzer R: Cytokine-induced siWkness behavior: where do we stand? Brain Behav Immun 2001, 15: 7-24.
28. Yirmiya R, Weidenfeld J, Pollak Y, et al.: Cytokines, "depression due to a general medical condition," and antidepressant drugs. Adv Exp Med Biol 1999, 461: 283-316.
29. Dietrich J, Han R, Yang Y, et al.: CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006, 5: 22.
30. Han R, Yang YM, Dietrich J, et al.: Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol 2008, 7: 12.
31. Sheline GE, Wara WM, Smith V: Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 1980, 6: 1215-1228.
32. Klein M, Heimans JJ, Aaronson NK, et al.: Effect of radiotherapy and other treatment-related factors on midterm to long-term cognitive sequelae in low-grade gliomas: A comparative study. Lancet 2002, 360: 1361-1368.
33. DeAngelis LM: Management of brain metastases. Cancer Invest 1994, 12: 156-165.
34. Ruben JD, Dally M, Bailey M, et al.: Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 2006, 65: 499-508.
35. Gutin PH, Prados MD, Phillips TL, et al.: External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2. Int J Radiat Oncol Biol Phys 1991, 21: 601-606.
36. Floyd NS, Woo SY, Teh BS, et al.: Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2004, 58: 721-726.
37. Forsyth PA, Kelly PJ, Cascino TL, et al.: Radiation necrosis or glioma recurrence: Is computer-assisted stereotactic biopsy useful? J Neurosurg 1995, 82: 436-444.
38. Elie M, Cole MG, Primeau FJ, et al.: Delirium risk factors in elderly hospitalized patients. J Gen Intern Med 1998, 13: 204-212.
39. McQuay HJ, Carroll D, Faura CC, et al.: Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther 1990, 48: 236-244.
40. Lawlor PG: The panorama of opioid-related cognitive dysfunction in patients with cancer: A critical literature appraisal. Cancer 2002, 94: 1836-1853.
41. Flacker JM, Lipsitz LA: Serum anticholinergic activity changes with acute illness in elderly medical patients. J Gerontol A Biol Sci Med Sci 1999, 54: M12-M16.
42. Eisendrath SJ, Goldman B, Douglas J, et al.: Meperidine-induced delirium. Am J Psychiatry 1987, 144: 1062-1065.
43. Marcantonio ER, Juarez G, Goldman L, et al.: The relationship of postoperative delirium with psychoactive medications. JAMA 1994, 272: 1518-1522.
44. Vainio A, Ollila J, Matikainen E, et al.: Driving ability in cancer patients receiving long-term morphine analgesia. Lancet 1995, 346: 667-670.
45. Meyers CA, Grous JJ, Ford KM, et al.: Multifaceted models for assisting quality of life in brain cancer therapy trials [abstract]. Drug Inf J 1996, 30: 856-857.
46. Shaw EG, Rosdhal R, D'Agostino RB, et al.: Phase II study of donepezil in irradiated brain tumor patients: Effect on cognitive function, mood, and quality of life. J Clin Oncol 2006, 24: 1415-1420.
47. Gonzalez J, Kumar AJ, Conrad CA, et al.: Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007, 67: 323-326.
48. Winkler F, Kozin SV, Tong RT, et al.: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6: 553-563.
49. Robertson IH: Cognitive rehabilitation in neurologic disease. Curr Opin Neurol 1993, 6: 756-760.
50. Pizzamiglio L, Antonucci G, Judica A, et al.: Cognitive rehabilitation of the hemineglect disorder in chronic patients with unilateral right brain damage. J Clin Exp Neuropsychol 1992, 14: 901-923.
51. Garrard P, Farnham C, Thompson AJ, et al.: Rehabilitation of the cancer patient: Experience in a neurological unit. Neurorehabil Neural Repair 2004, 18: 76-79.
52. Rogers MP, Mendoza AP: Psychiatric management of brain tumor patients. In Cancer of the Nervous System, edn 2. Edited by Black PM, Loeffler JS. Philadelphia: Lippincott Williams & Wilkins; 2005:255-277.